ライフサイエンスコーパス: 131I

1 131I alone had no effect on MM1 tumor growth.

2 131I MIBG scanning has a high diagnostic accuracy in det

3 131I-3F8 pharmacokinetics were studied by serial CSF and

4 131I-anti-B1 (CD20) radioimmunotherapy (RIT) is a promis

5 131I-meta-iodobenzylguanidine (MIBG) was used to assess

6 131I-MIBG with myeloablative chemotherapy is feasible an

7 131I-TM-601 bound to the tumor periphery and demonstrate

8 131I-TM-601 provides a reliable estimate for primary tum

9 rest and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrCl.

10 ), 99mTc-MIBI (rest and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA an

11 125I/131I-Rh 123 was stable in serum in vitro but rapidly met

12 125I/131I-Rh 123 was synthesized in modest yields (40-45%).

13 rolyzed TG from the heart tissue showed 125I/131I components with the same retention times as shorter

14 of acid-hydrolyzed urine gave a single 125I/131I component with the same relative retention time as

15 740,000 Ci (2.73 x 10(16) Bq) of iodine 131 (131I) were released to the atmosphere from the Hanford N

16 hy (PET), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In-pentetreoti

17 Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted therapy for t

18 or moderate doses of radioactive iodine-131 (131I) at a young age is a public health concern.

19 dose of the therapeutic isotope iodine-131 (131I) without evidence of recurrence up to 5 months afte

20 iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) targeting GD2-positive CNS/LM disease in a pha

21 at, after i.v. injection, iodinated JV-1-42 (131I-JV-1-42) enters the brain intact at a rate of 0.851

22 ctions of 300 microCi of no-carrier-added 5-[131I]-2'-fluoro-1-beta-D-arabinofuranosyluracil (FIAU) a

23 or volume in 73% of the animals administered 131I-DLT-labeled RS11 remained smaller than at the time

24 and dosimetry of intracavitary-administered 131I-TM-601 in patients with recurrent glioma.

25 umor radiation dose per unit of administered 131I was 1.0 Gy/GBq (3.7 rad/mCi) for patients with NHL

26 diation was 3.9% in 66 patients administered 131I-labeled antibodies and was 9.1% in 18 patients admi

27 e limit of 75 cGy (75 rad), the administered 131I activity ranged from 2.1 to 6.5 GBq (56 to 175 mCi)

28 e results demonstrate that i.v.-administered 131I-JV-1-42 readily crosses the blood-brain barrier and

29 es were obtained on these patients 7 d after 131I therapy and were compared with the diagnostic scans

30 apy and every 12 h for another 5 doses after 131I ingestion.

31 An additional dose of 0.1 mg AP 24 h after 131I-B72.3 further improved the therapeutic outcome (T(q

32 awake and also for the first 3 nights after 131I therapy.

33 and image quality, and images obtained after 131I therapy did not reveal unknown metastatic foci.

34 mal yield compared with scans obtained after 131I therapy.

35 ents with increased risk of recurrence after 131I therapy.

36 ese new regulations on patient release after 131I anti-B1 therapy for the treatment of non-Hodgkin's

37 arpine, 5 mg orally every 8 h for 1 wk after 131I therapy, would reduce salivary symptoms.

38 th the anti-MHCII, but surprisingly, allowed 131I-anti-Id to cure most mice.

39 Although 131I-iodine (RAI) therapy is a mainstay in the treatment

40 dose equivalent to the public exposed to an 131I anti-B1 patient discharged without hospitalization

41 phantoms consisted of spheres filled with an 131I solution to model intratumoral administration of ra

42 The analogue 131I-metaiodobenzylguanidine (MIBG), which is specifical

43 dionuclides of interest: 90Y, 99mTc,123I and 131I.

44 The relative distributions of 125I and 131I in the lipid, aqueous and pellet samples were simil

45 The distributions of 125I and 131I in the organic (lipid), aqueous and pellet samples

46 By TLC, radioactive components of 125I and 131I in the urine had the same TLC mobility as hippuric

47 Distribution of 125I and 131I in the various components of the lipid extracts obs

48 of the FFA fraction showed similar 125I and 131I profiles, corresponding to BMIPP, and the alpha-met

49 The radioiodines 123I, 124I, 125I and 131I were accommodated as tracers and therapeutic agents

50 odinated with 2 isotopes of iodine (125I and 131I) to separately determine the PS and Vp values.

51 125I-labeled mildly cationic glyco-Fab and 131I-labeled nonglycolated Fab had similar distributions

52 stributions of 125I-labeled sa-glyco-Fab and 131I-labeled nonglycolated Fab were evaluated in normal

53 point, 38% of the mice treated with 5-FU and 131I-mAb A33 were disease free at 276 days compared to n

54 abeled sa-glyco-Fab (4 microCi/1 microg) and 131I-labeled nonglycolated Fab (5 microCi/1 microg) in T

55 I-labeled glyco-Fab (3 microCi/1 microg) and 131I-labeled nonglycolated Fab (5 microCi/1 microg).

56 sted of a dosimetric dose of tositumomab and 131I-labeled tositumomab followed one week later by a th

57 ethylenetriaminepentaacetic acid (DTPA) and [131I]orthoiodohippurate (OIH) were simultaneously perfor

58 vered by a radiolabeled monoclonal antibody, 131I-labeled A33, that targets colorectal carcinoma, wit

59 of radioactivity (TK expression measured as 131I-labeled FIAU % dose/g) and coexpressed lacZ gene ac

60 n beta energy-emitting radionuclide, such as 131I, accurate computation of the mouse bone marrow dose

61 ta- and gamma-emitting radionuclides such as 131I, which are widely used in radioimmunotherapy, are n

62 dase (ATPO) in relation to measurement-based 131I dose estimates in a Belarusian cohort of 10,827 ind

63 renal collecting system is expected, because 131I excretion is primarily by glomerular filtration.

64 The association between 131I dose and hypothyroidism in the Belarusian cohort is

65 Sensitive and specific, whole-body 131I scintigraphy remains an important technique for dia

66 y than the Auger electron emitters, but both 131I and 90Y, and particularly 131I, still had high leve

67 Our protocols for imaging both 131I-MIBG and 123I-MIBG, along with the normal distribut

68 ry symptoms of pain and xerostomia caused by 131I therapy for papillary and follicular thyroid carcin

69 ulted in selective killing of these cells by 131I in an in vitro clonogenic assay.

70 geted hematopoietic irradiation delivered by 131I-anti-CD45 antibody has been combined with conventio

71 y in which targeted irradiation delivered by 131I-anti-CD45 antibody was combined with targeted busul

72 unit dose of radiation therapy delivered by 131I-labeled A33 monoclonal antibodies was approximately

73 cal removal of the thyroid gland followed by 131I ablation of residual thyroid tissue.

74 tion of residual thyroid cancer not found by 131I scans in patients with increased risk of recurrence

75 e to the delivered disintegrations per cell, 131I and 67Ga were the most potent of the radionuclides

76 ver, quantitative data are sparse concerning 131I-related risk of these common diseases.

77 In contrast, 131I-anti-Id, despite targeting irradiation and having t

78 of 131I-DLT-labeled MAb RS11 to conventional 131I-labeled RS11 and an untreated control group.

79 her tumor radiation doses than corresponding 131I-labeled monoclonal antibodies, the radiation dosime

80 tions of chemical-shift MRI, noncontrast CT, 131I-6beta-iodomethylnorcholesterol (NP-59) scintigraphy

81 d antibody, protected mice for only 30 days; 131I-anti-CD19 and anti-CD22 were therapeutically inacti

82 Diagnostic 131I scans were compared with postablation scans for evi

83 visualized on routine preablation diagnostic 131I scintigraphy but was obvious on post-therapeutic wh

84 icity and therapeutic potential of high-dose 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclon

85 25I, and to evaluate beta-particle emitters, 131I and 90Y.

86 8 and none occurred with the (R)-enantiomer [131I](R)-8 in sections from CB1 receptor knockout mice.

87 ic binding was seen with the (S)-enantiomer [131I](S)-8 and none occurred with the (R)-enantiomer [13

88 hens evidence of the effect of environmental 131I exposure during childhood on hypothyroidism, but no

89 sease resulting from prolonged environmental 131I exposure is poorly understood.

90 Mean (median) estimated 131I thyroid dose was 0.54 (0.23) Gy (range, 0.001-26.6

91 owever, currently used methods of estimating 131I-MIBG uptake in vivo may be too inaccurate to proper

92 itored with dosimeters for 10 days following 131I administration.

93 For 131I, the S (prostate<--urinary bladder contents) and S

94 the full geometry were 46%, 24% and 10% for 131I-, 186Re- and 90Y-radiolabeled antibodies, respectiv

95 whole-body sources were 61%, 40% and 29% for 131I, 186Re and 90Y, respectively.

96 ination with yields of approximately 70% for 131I and 60% for 124I.

97 abeling have been successfully addressed for 131I anti-B1 therapy.

98 adrupling time (T(q)) was 14.2 +/- 3.3 d for 131I-B72.3 alone versus 26.0 +/- 3.6 d for 131I-B72.3 pl

99 r 131I-B72.3 alone versus 26.0 +/- 3.6 d for 131I-B72.3 plus 0.1 mg AP (P < 0.001).

100 volution method to perform the dosimetry for 131I-labeled antibodies in soft tissues.

101 Patient-specific S factors for 131I were calculated with the MCNPX2.5.0 Monte Carlo cod

102 Data are also tabulated for 131I in 0.1-mm voxels for use in autoradiography.

103 99mTc and 123I are tenfold lower; those for 131I are fivefold lower and those for 90Y are 20% lower.

104 normal and tumor-bearing mice with all four 131I-labeled preparations.

105 roid autoimmunity, since CD4(+) T cells from 131I-treated PVG.RT1(u) rats were as effective as those

106 CD4(+) T cells, CD4(+)CD8(-) thymocytes from 131I-treated PVG donors were still able to prevent thyro

107 One patient received 9.95 GBq 131I-MN-14 F(ab)2, for an initial dose of 656 cGy to cri

108 In the case presented here, 131I activity within the renal cyst supports the concept

109 A method of quantitatively imaging 131I distributions in brain tumors from intratumoral adm

110 In 131I SPECT, image quality and quantification accuracy ar

111 In 131I SPECT, object scatter as well as collimator scatter

112 echniques that compensate for such events in 131I imaging.

113 collimator resulted in a large reduction in 131I penetration, which is especially significant in RIT

114 Seventy patients were receiving initial 131I therapy, and 29 had undergone prior radioablative t

115 tics and radiation dosimetry for the initial 131I-Lym-1 therapy dose in patients with NHL and CLL and

116 We present a case of intense 131I localization in a previously unsuspected large rena

117 A phase I/II clinical trial of intracavitary 131I-TM-601 in adult patients with recurrent high-grade

118 ration of larger activities of sodium iodide 131I than previously permitted.

119 nt of thyroid diseases by radioactive iodine 131I.

120 rmaceutical [131I]meta-iodobenzylguanidine ([131I]MIBG) which results in kill of clonogens.

121 ng great promise for the treatment of NHL is 131I-labeled anti-B1.

122 Through dosing charts, maximum 131I therapy doses may easily be calculated.

123 lication of the code and guidelines, maximum 131I doses for patients undergoing thyroid remnant ablat

124 Augmenting the dose of 9.25 MBq 131I-B72.3 with a single administration of 0.1 mg AP del

125 At the maximum tolerated dose of 3700 MBq 131I-labeled 81C6 MAb, the absorbed doses to the SCRC in

126 reated with 102 to 298 mCi (3774-11 026 MBq) 131I, delivering an estimated 5.3 to 19 (mean, 11.3) Gy

127 A single dose of 10 mCi 131I-TM-601 was well tolerated for 0.25 to 1.0 mg TM-601

128 donor granulocytes and T cells after 0.5 mCi 131I (estimated 17 Gy to marrow) or 8 Gy TBI.

129 h 30F11 antibody labeled with 0.1 to 1.5 mCi 131I and/or total body irradiation (TBI), followed by T-

130 urred in only 3 of 11 mice receiving 1.5 mCi 131I delivered by anti-CD45 antibody.

131 ieved in 22 of 23 animals receiving 0.75 mCi 131I delivered by anti-CD45 antibody combined with 8 Gy

132 a single-dose injection of 370 MBq (10 mCi) 131I-TM-601 (0.25-1.0 mg of 131I-TM-601) 2-4 wks after s

133 idism may be treated with 7400 MBq (200 mCi) 131I or more.

134 y labeled with 185 to 370 Mbq (5 to 10 mCi) [131I]-tracer for dosimetry purposes followed 10 days lat

135 ty after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patients with resistant neurobla

136 inistration of 131I-metaiodobenzylguanidine (131I-MIBG) continues to be a promising treatment for neu

137 single doses of 350 microCi and 500 microCi 131I-labeled NA1/34 significantly (p < 0.001) delayed xe

138 to regrow after administration of 7 MBq/ml [131I]MIBG.

139 y-three of the 61 patients had both negative 131I WBS findings and elevated thyroglobulin levels.

140 s were obtained in 54 patients with negative 131I scans 3-25 y (median 7.9 y) after the first postsur

141 Nonbound 131I-TM-601 was eliminated by 48 h after injection with

142 cine (MAG3) is less than the clearances of o-131I-iodohippurate (OIH) and 99mTc-labeled DD- and LL-et

143 We have examined the ability of 131I-anti-CD45 antibody to facilitate engraftment in Ly5

144 e effect of protein dose on the accretion of 131I-DLT-labeled MAb RS11 in tumor and nontumor tissues,

145 tively killed by the induced accumulation of 131I.

146 Accuracy of 131I tumor quantification after radioimmunotherapy (RIT)

147 o the lesion from the diagnostic activity of 131I, because of uncertainty about the tumor mass.

148 The MTD for administration of 131I-labeled 81C6 into the SCRCs of previously irradiate

149 High-dose administration of 131I-metaiodobenzylguanidine (131I-MIBG) continues to be

150 not appear to be influenced by the amount of 131I or Lym-1 within the ranges administered.

151 his study suggest that further assessment of 131I WBS-negative, thyroglobulin-positive patients by 18

152 e found significant positive associations of 131I dose with hypothyroidism (mainly subclinical and an

153 Tumor concentration of 131I and radiation dose per gigabecquerel were inversely

154 latter group had less tumor concentration of 131I.

155 A single one-week course of 131I-tositumomab therapy as initial treatment can induce

156 lete clinical remission, using two cycles of 131I-labeled murine MN-14 anti-CEA monoclonal antibody (

157 slightly shorter than the physical decay of 131I (6.3 vs. 8.0 d).

158 escribes the pharmacokinetic distribution of 131I-labeled G250 antibody is developed.

159 ents were treated with escalating dosages of 131I (starting dose of 20 mCi with a 20-mCi escalation i

160 te the effect of a diagnostic tracer dose of 131I on the uptake of the therapeutic dose of 1311 in th

161 eveloped that calculates the maximum dose of 131I that may be dispensed to an outpatient.

162 h NHL, who were given first a tracer dose of 131I-anti-B1 and then RIT, each preceded by infusion of

163 l cancers were administered a tracer dose of 131I-MAb CC49.

164 The minimum dose of 131I-MIBG for 10 of the 11 responders was 12 mCi/kg.

165 surgery, patients received a single dose of 131I-TM-601 from one of three dosing panels (0.25, 0.50,

166 utpatient RIT with nonmyeloablative doses of 131I should be feasible for all patients under current N

167 imum tolerated dose for each of two doses of 131I-Lym-1 was 3.7 GBq/m2 (total 7.4 GBq/m2 [100 mCi/m2,

168 of administering high myeloablative doses of 131I-MN-14 F(ab)2 with AHSCR in patients with metastatic

169 received individualized therapeutic doses of 131I-tositumomab (median, 19.7 GBq [531 mCi]) to deliver

170 f this study was to perform the dosimetry of 131I-labeled 81C6 monoclonal antibody (MAb) in patients

171 In conclusion, a therapeutic effect of 131I has been demonstrated in prostate cancer cells afte

172 ccumulation and therapeutic effectiveness of 131I in NIS-transfected prostate cancer cells in vitro a

173 ow any effect of stunning on the efficacy of 131I therapy for differentiated thyroid carcinoma.

174 led antibodies showed a rapid elimination of 131I from the cell and a high retention of (111)In.

175 T/CT 3-4 d after receiving 3.96+/-0.5 GBq of 131I for radioablation of thyroid remnants after a thyro

176 The therapeutic index of 131I-Lym-1 was favorable, although the index for patient

177 Following i.t. injection of 131I-BSD-EGF, 21.8% of the injected dose per gram tissue

178 ents were treated with a single injection of 131I-labeled 81C6.

179 compared the effect of single injections of 131I-DLT-labeled MAb RS11 to conventional 131I-labeled R

180 at the initial dose level using 12 mCi/kg of 131I-MIBG and reduced chemotherapy, one in six patients

181 lls (n = 148) were treated with 18 mCi/kg of 131I-MIBG.

182 x with escalating doses of 3 to 18 mCi/kg of 131I-MIBG.

183 ders 3 constants: the effective half-life of 131I during the preequilibrium period, and the effective

184 rium period, and the effective half-lives of 131I in both the thyroidal component and the extrathyroi

185 Thyroid stunning can occur with 185 MBq of 131I in diagnostic imaging.

186 with escalating activities (3.7-18.5 MBq) of 131I-labeled A33 or 10 fractions of 320 kVp x-rays (frac

187 d intravenously with low doses (9.25 MBq) of 131I-labeled mAb B72.3 in combination with various intra

188 -1-tk and lacZ gene coexpression, 0.2 mCi of 131I-labeled FIAU was injected i.v. 24 h after the last

189 phase II study, administration of 100 mCi of 131I-m81C6 to recurrent malignant glioma patients follow

190 In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically cre

191 0 mg of TM-601), each labeled with 10 mCi of 131I.

192 e precise, patient-specific dose (in mCi) of 131I anti-B1 antibody needed to deliver a specified whol

193 rove in vivo localization and measurement of 131I-MIBG uptake in tumors.

194 370 MBq (10 mCi) 131I-TM-601 (0.25-1.0 mg of 131I-TM-601) 2-4 wks after surgery.

195 A single dose of 100 microCi of 131I-DLT-RS11 was found to cause tumor regression.

196 xperiments, a single dose of 1500 microCi of 131I-labeled monoclonal antibody (MAb) Mc5 was given to

197 This unexpected potency of 131I-anti-Id late in the disease appeared to result from

198 ocalized radiolabeling in the preparation of 131I-labeled antibodies for RIT.

199 cy can be achieved for VOI quantification of 131I using SPECT with an UHE collimator and a constant c

200 posed as children to atmospheric releases of 131I from Hanford.

201 Encouraged by the results of 131I-Lym-1 therapy trials for patients with B-cell non-H

202 first trial suggest that phase II studies of 131I-TM-601 are indicated.

203 rmacokinetic data from a Phase I-II study of 131I-G250 murine antibody against renal cell carcinoma w

204 We report a dose escalation study of 131I-MIBG to define dose-limiting toxicity without and w

205 ver, spleen and kidneys, compared to that of 131I-MN-14.

206 tory index using MAG3 is the same as that of 131I-OIH, 0.8-1.2.

207 ercaptotriacetylglycine (MAG3), like that of 131I-orthoiodohippurate (OIH), can be used to identify a

208 Cu has beta emissions comparable to those of 131I but has gamma emissions more favorable for imaging.

209 The effective half-time of 131I measured in athyrotic patients was used together wi

210 We administered 36 treatments of 131I doses up to 120 mCi to 34 previously irradiated pat

211 ose administration, the fractional uptake of 131I by residual thyroid tissue or metastasis, and the d

212 adioiodine treatment of focal neck uptake of 131I were studied.

213 al mass that demonstrated abnormal uptake of 131I-MIBG indicative of metastatic carcinoid tumor to th

214 A study of the use of 131I-labeled anti-B1 monoclonal antibody, proceeded by a

215 udy was to determine the diagnostic value of 131I SPECT/spiral CT (SPECT/CT) on nodal staging of pati

216 There was no accumulation of [131I]FIAU-derived radioactivity in tumors that were inje

217 The amount of [131I]FIBG retained by SK-N-SH cells was significantly hi

218 The specific binding of [131I]FIBG remained fairly constant (45%-60%) over a 2-3-

219 We now report 17-fold enhancement of [131I]MIBG uptake by UVW glioma cells transfected with th

220 by individualized therapeutic infusions of [131I]tositumomab (median, 19.4 Gbq [525 mCi]; range, 12.

221 The level of [131I]FIAU-derived radioactivity accumulation (HSV1-tk ex

222 emonstrated highly specific localization of [131I]FIAU-derived radioactivity to the area of ADV.RSV-t

223 Intra-Ommaya 131I-3F8 was generally well tolerated; the maximum-toler

224 tic injection (10 to 20 mCi) of intra-Ommaya 131I-3F8.

225 rent in age, sex, type of thyroid cancer, or 131I activity administered (P > 0.05).

226 ere similar before and after chemotherapy or 131I-MIBG treatment, except for a trend toward lower pos

227 Thirty patients who received outpatient 131I therapy following thyroidectomy for differentiated

228 old members of patients receiving outpatient 131I therapy were well below the limit (5.0 mSv) mandate

229 ers, but both 131I and 90Y, and particularly 131I, still had high levels of specificity.

230 Tables for maximum allowable patient 131I doses were derived on the basis of this model.

231 The new regulations will permit 131I anti-B1 therapy to be conducted on an outpatient ba

232 False-positive 131I localization is well recognized and can occur in a

233 (median 7.9 y) after the first postsurgical 131I therapy.

234 undergoing surveillance imaging after prior 131I ablation therapy with positive scans, 24-h images w

235 f the two isomers, a mixture of [125I]-3(R)/[131I]-3(S)-BMIPP was administered to fasted female Fishe

236 tients had negative findings on radioiodine (131I) whole-body scintigraphy (WBS).

237 finity for uptake of the radiopharmaceutical 131I-metaiodobenzylguanidine (MIBG) (3).

238 ive accumulation of the radiopharmaceutical [131I]meta-iodobenzylguanidine ([131I]MIBG) which results

239 The patients received 131I doses ranging from 2.8 to 5.6 GBq (mean, 4.3 GBq).

240 A total of 33 clinical patients received 131I-tositumomab (n=23) or 90Y-ibritumomab tiuxetan (n=1

241 ernobyl thyroid cancer patients who received 131I ablation treatment.

242 Ninety-nine patients who received 131I-labeled MN-14 or NP-4 anti-CEA MAbs for the treatme

243 in SUVlean max between patients who received 131I-tositumomab and those who received 90Y-ibritumomab

244 Data on more than 50 patients receiving 131I anti-B1 therapy, an investigational therapy for non

245 ants' thyroid radiation doses from Hanford's 131I releases were estimated from interview data regardi

246 Drug Administration, using patient-specific 131I-m81C6 dosing, to deliver 44 Gy to the SCRC followed

247 In our study, 131I doses to household members of patients receiving ou

248 Epidemiologic evidence demonstrates that 131I treatment for thyroid cancer or hyperthyroidism in

249 sing all 3 imaging parameters indicated that 131I-TM-601-determined tumor volumes more closely parall

250 It is known that 131I breast uptake may be functional within the mammary

251 Model simulations showed that 131I-labeled biotin with the streptavidinylated F(ab')2

252 n administered early in disease (day 4), the 131I-anti-MHCII MoAb cured tumors as a result of targete

253 h neuroblastoma or pheochromocytoma, and the 131I-labeled form was recently approved by the Food and

254 lular uptake and metabolic processing of the 131I- and (111)In-labeled antibodies showed a rapid elim

255 owed for dose estimations, which suggest the 131I-labeled scFv-Fc H310A/H435Q as a promising candidat

256 Pretargeting with the 131I- and 124I-labeled peptide was tested in nude mice b

257 r a single i.p. application of a therapeutic 131I dose (3 mCi), significant tumor reduction was achie

258 ment of outpatients treated with therapeutic 131I than did preceding regulations.

259 Therefore, 131I-labeled anti-CD45 antibody has been used in combina

260 hat exposure during infancy and childhood to 131I at the dose levels (median, 97 mGy; mean, 174 mGy)

261 ficant additive antitumor effect compared to 131I-mAb A33 alone or to chemotherapy alone.

262 tient kinetics and that is not restricted to 131I as a tracer and therapeutic agent.

263 ritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogam

264 technique for imaging and quantifying total 131I activity in regions the size of brain tumors.

265 y-two (88%) of 59 patients receiving a trace 131I-labeled dose of 0.5 mg/kg anti-CD45 murine antibody

266 low tracers and a vascular reference tracer (131I-albumin) were introduced simultaneously as a compac

267 vity and resolution were characterized using 131I point-source acquisitions with high-resolution lead

268 , but important advances have occurred using 131I metaiodobenzylguanidine (MIBG).

269 riplegia performed over a 21-y period, using 131I-orthoiodohippurate (OIH) through 1990 and MAG3 sinc

270 high-dose radioimmunotherapy (HD-RIT) using 131I-anti-CD20 (n = 27) or conventional high-dose therap

271 Thus, targeted radiation delivered via 131I-anti-CD45 antibody can enable engraftment of congen

272 h normal GFR (> or = 100 mL/min/1.73 m2) was 131I-MIBG 12 mCi/kg, carboplatin 1,500 mg/m2, etoposide

273 Two cohort years were reviewed: 1988, when 131I-orthoiodohippurate (OIH) was used; and 1995, when 9

274 sistant MM1 tumors regressed completely when 131I was administered 9 days after a single intravenous

275 ution data from this trial to assess whether 131I-TM-601 might be useful in determining tumor extent.

276 e of thyroid dysfunction in association with 131I exposure during childhood (</= 18 years) due to fal

277 apeutic gene for myeloma in combination with 131I needs further exploration.

278 h or without leucovorin) in combination with 131I-mAb A33 showed a statistically significant additive

279 quivalent to an individual from contact with 131I anti-B1 radioimmunotherapy (RIT) patients released

280 and CLL and to compare tumor dosimetry with 131I-Lym-1 dosing and other patient parameters.

281 All four mAbs could be labeled with 131I up to a specific activity of 350 MBq/mg with no or

282 er, respectively, than for L8A4 labeled with 131I using Iodogen.

283 lymphocytic leukemia (CLL) when labeled with 131I.

284 Blood volumes were measured with 131I-labeled albumin and hematocrit.

285 ns are presented for radioimmunotherapy with 131I anti-B1 antibody, although they are likely to be us

286 nt data suggest that radioimmunotherapy with 131I-tositumomab or 90Y-ibritumomab tiuxetan not only in

287 J533, J591, and 7E11 were radiolabeled with 131I and evaluated in competitive and saturation binding

288 oxicity after radioimmunotherapy (RAIT) with 131I-labeled anticarcinoembryonic antigen (anti-CEA) mon

289 Adrenal scintigraphy with 131I-labeled 6-beta-iodomethyl-19-norcholesterol (NP-59)

290 we compared the three EC stereoisomers with 131I-orthoiodohippurate (OIH) in a series of rats and hu

291 d undergone prior radioablative therapy with 131I.

292 se rate and low nonhematologic toxicity with 131I-MIBG suggest incorporation of this agent into initi

293 with stage 3 or 4 lymphoma were treated with 131I-Lym-1 (0.74-8.04 GBq [20-217 mCi]) in either a maxi

294 oids were ablated in utero by treatment with 131I, were unable to prevent disease development upon ad

295 ity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2).

296 Treatment with 131I-MIBG has mainly hematologic toxicity, which can be

297 al therapy a single course of treatment with 131I-tositumomab therapy (registered as Tositumomab and

298 mouse hippocampal membrane preparation with [131I](R)-8 as radioligand, racemic 8 exhibited a K(i) va

299 -dependent susceptibility to treatment with [131I]MIBG.

300 K+ T cells labeled in vitro or in vivo with [131I]FIAU or [124I]FIAU can be noninvasively tracked in